Fulgent Genetics, Inc. (FLGT) AI Stock Analysis

Fulgent Genetics, Inc. provides molecular diagnostic and genetic testing services in the United States and internationally. Its diagnostic portfolio includes COVID-19 testing, next-generation sequencing, RT-PCR, and antigen-based tests. The company offers carrier screening panels such as Beacon, oncology panels such as Focus and Comprehensive, solid tumor profiling, and rapid whole genome testing for children in intensive care units. It also provides newborn genetic analysis panels, single front-line tests for ataxia-related variants, patient-initiated testing via Picture Genetics, and whole exome sequencing. Additional diagnostic services encompass flow cytometry, fluorescence in-situ hybridization, immunohistochemistry, and cytogenetics for chromosome analysis.

Fulgent Genetics saw revenue drop from $992.6M in FY2021 to $283.5M in FY2024 before increasing 13.8% to $322.7M in FY2025. Gross margin contracted from 78.3% in FY2021 to 40.6% in FY2025, while operating margin shifted from 10.5% to -28.2%. Net income was -$60.5M in FY2025, compared to $104.3M in FY2021. For the trailing twelve months, revenue reached $323.9M with an operating margin of -39.4% and an EPS of -$2.81. In the latest quarter ended June 30, 2026, quarterly revenue increased 4.4% year-over-year, while quarterly earnings declined 98.6% year-over-year.

As of June 30, 2026, Fulgent Genetics held $257.0M in cash and short-term investments against total debt of $9.4M, resulting in net cash of $247.6M. The company reported shareholders' equity of $1.00B and a current ratio of 6.34, with a debt-to-equity ratio of 0.01. During FY2025, operating cash flow was -$101.6M and free cash flow was -$124.2M. Capital expenditures totaled $22.6M, while the company repurchased $13.9M in shares, contributing to a 5-year share count reduction of 10.2%.

At a last close of $19.81, Fulgent Genetics trades at an enterprise value of $337.6M and a price-to-sales ratio of 1.7x, below the 4.1x median of its US-listed Healthcare peers. Its forward P/E of 7.7x and EV/EBITDA of 2.3x also sit below the peer medians of 17.3x and 12.0x, respectively. Over the past year, FLGT shares fell 13.1%, lagging the 16.8% return of the S&P 500 benchmark. Over the 5-year period, the stock fell 74.6%, while the S&P 500 gained 83.0%.

Wall Street coverage on Fulgent Genetics consists of 1 Hold rating, with 0 Buy and 0 Sell ratings. The analyst mean price target is $19.00, representing a 4.1% discount to the last close of $19.81. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $331.7M and an EPS of -$2.27. Fulgent has exceeded EPS expectations in 2 of the past 4 quarters, and its next earnings release is scheduled for November 6, 2026.

This page is an AI-written research summary of Fulgent Genetics, Inc. (FLGT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: FLGT income statement, FLGT balance sheet, FLGT key metrics, FLGT analyst forecast, FLGT chart. See the FLGT stock overview for the latest quote and news.